Zydus gets USFDA nod for capsules to treat dementia
DSIJ Intelligence / 05 Aug 2017
Zydus Cadila announced on Saturday that the company has received the final approval from USFDA to market Memantine Hydrochloride Extended Release capsules in strengths of 7 mg, 14 mg, 21 mg and 28 mg.
Zydus Cadila announced on Saturday that the company has received the final approval from USFDA to market Memantine Hydrochloride Extended Release capsules in strengths of 7 mg, 14 mg, 21 mg and 28 mg.
The drug is used in the treatment of moderate to serve dementia of the Alzheimer’s type and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The sale of the capsules is estimated at USD 1.1 billion.
Meanwhile, the stock on Friday closed lower by 2.66% at Rs 531 per share on the BSE. It touched its intraday high and low at Rs 544.50 and Rs 523.30 per share respectively. It attracted total traded volume of 8,59,002 shares and traded value of Rs 4,557.86 lakh on the NSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.